- Stocks
- Healthcare
- NASDAQ: ACRX

Price (delayed)

$1.11

Market cap

$12.13M

P/E Ratio

0.18

Dividend/share

N/A

EPS

$6.16

Enterprise value

$2.14M

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers

Acelrx Pharmaceuticals's debt has plunged by 80% YoY and by 38% from the previous quarter

The price to earnings (P/E) is 64% lower than the last 4 quarters average of 0.5

ACRX's equity has soared by 137% YoY but it is down by 35% from the previous quarter

The gross margin has dropped by 105% year-on-year but it has grown by 22% since the previous quarter

ACRX's revenue is down by 42% YoY and by 25% QoQ

The quick ratio has declined by 39% year-on-year and by 7% since the previous quarter

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.acelrx.com

What are the main financial stats of ACRX

Market
Valuations
Earnings

Shares outstanding

10.92M

Market cap

$12.13M

Enterprise value

$2.14M

Price to earnings (P/E)

0.18

Price to book (P/B)

0.85

Price to sales (P/S)

9.1

EV/EBIT

0.04

EV/EBITDA

0.04

EV/Sales

1.61

Revenue

$1.33M

EBIT

$49.12M

EBITDA

$50.61M

Free cash flow

-$25.02M

Per share
Balance sheet
Liquidity

EPS

$6.16

Free cash flow per share

-$2.3

Book value per share

$1.3

Revenue per share

$0.12

TBVPS

$2.41

Total assets

$26.29M

Total liabilities

$12.05M

Debt

$3.37M

Equity

$14.24M

Working capital

$7.89M

Debt to equity

0.24

Current ratio

1.83

Quick ratio

1.41

Net debt/EBITDA

-0.2

Margins
Efficiency
Dividend

EBITDA margin

3,808.1%

Gross margin

-36%

Net margin

3,632.6%

Operating margin

-2,480.5%

Return on assets

96.5%

Return on equity

178.3%

Return on invested capital

229%

Return on capital employed

291.9%

Return on sales

3,696.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Acelrx Pharmaceuticals stock price performed over time

Intraday

16.84%

1 week

40.31%

1 month

64.15%

1 year

-74.89%

YTD

-50.88%

QTD

68.69%

How have Acelrx Pharmaceuticals's revenue and profit performed over time

Revenue

$1.33M

Gross profit

-$478,000

Operating income

-$32.97M

Net income

$48.28M

Gross margin

-36%

Net margin

3,632.6%

The gross margin has dropped by 105% year-on-year but it has grown by 22% since the previous quarter

ACRX's operating margin has shrunk by 80% YoY and by 20% QoQ

ACRX's revenue is down by 42% YoY and by 25% QoQ

ACRX's gross profit is up by 42% QoQ but it is down by 18% YoY

What is Acelrx Pharmaceuticals's growth rate over time

What is Acelrx Pharmaceuticals stock price valuation

P/E

0.18

P/B

0.85

P/S

9.1

EV/EBIT

0.04

EV/EBITDA

0.04

EV/Sales

1.61

The price to earnings (P/E) is 64% lower than the last 4 quarters average of 0.5

ACRX's EPS is up by 8% since the previous quarter

ACRX's equity has soared by 137% YoY but it is down by 35% from the previous quarter

The P/B is 6% less than the last 4 quarters average of 0.9

ACRX's price to sales (P/S) is 80% lower than its 5-year quarterly average of 45.6 and 37% lower than its last 4 quarters average of 14.5

ACRX's revenue is down by 42% YoY and by 25% QoQ

How efficient is Acelrx Pharmaceuticals business performance

The company's return on equity has shrunk by 54% QoQ

The company's return on invested capital has surged by 51% QoQ

ACRX's return on sales is up by 34% since the previous quarter

ACRX's ROA is up by 28% since the previous quarter

What is ACRX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ACRX.

How did Acelrx Pharmaceuticals financials performed over time

Acelrx Pharmaceuticals's total assets is 118% higher than its total liabilities

ACRX's total liabilities has shrunk by 89% YoY and by 53% QoQ

Acelrx Pharmaceuticals's total assets has shrunk by 63% YoY and by 45% QoQ

Acelrx Pharmaceuticals's debt is 76% less than its equity

The debt to equity has soared by 156% YoY but it has contracted by 4% from the previous quarter

ACRX's equity has soared by 137% YoY but it is down by 35% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.